FDA Approval Flashcards
1
Q
Lurasidone indications
A
- Schizophrenia
- Depression in bipolar monotherapy
- Depression in bipolar w/Lithium or VPA
2
Q
Lurasidone contraindications
A
- Use w/CYP3A4 inhibitors or inducers
3
Q
Lurasidone warnings
A
- Increased mortality in adults w/ dementia-related psychosis (Not approved for dem-related psychosis)
- Increased suicidal thoughts in children & adolescents taking antidepressants
4
Q
Lurasidone precautions
A
- CVA in Dementia-related psychosis
- NMS: immediately d/c and monitor closely
- TD: D/c if clinically appropriate
- Metabolic Sxn
- Hyperprolactinemia
- Leukopenia/neutropenia/agranulocytosis
- OrthoHoTN/Syncope
5
Q
Lurasidone adverse reactions
A
- Somnolence, Akathisia, EPS, Nausea,
6
Q
Aripiprazole Indications
A
- schizophrenia
- acute mania & mixed episodes
- MDD adjunct
- Irritability a/w Autism
- Tourette’s
- agitation d/t sch or mania
7
Q
Aripiprazole adverse reactions
A
- Akathisia
- sedation/somnolence
- insomnia
- restlessness
- fatigue
- tremor
- EPS
- Sialorrhea
- Constipation
- Nausea
- blurred vision
- Peds: Headache, increased appetite
8
Q
Aripiprazole CYP3A4 and CYP2D6 inhibition
A
- If one, give half dose. if both give a quarter dose
9
Q
Aripiprazole CYP3A4 inducer
A
Double usual dose over 1-2 weeks
10
Q
Aripiprazole WARNINGS
A
- Increased mortality in adults w/ dementia-related psychosis (Not approved for dem-related psychosis)
- Increased suicidal thoughts in children & adolescents taking antidepressants
